NasdaqGM:SCYX

Stock Analysis Report

Executive Summary

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States.

Rewards

Trading at 96.4% below its fair value

Revenue is forecast to grow 65.94% per year

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($185K)

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

+ 2 more risks


Snowflake Analysis

Slightly overvalued with limited growth.

Share Price & News

How has SCYNEXIS's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SCYX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

16.7%

SCYX

-1.6%

US Pharmaceuticals

1.8%

US Market


1 Year Return

-29.0%

SCYX

6.7%

US Pharmaceuticals

20.1%

US Market

Return vs Industry: SCYX underperformed the US Pharmaceuticals industry which returned 6.7% over the past year.

Return vs Market: SCYX underperformed the US Market which returned 20.1% over the past year.


Shareholder returns

SCYXIndustryMarket
7 Day16.7%-1.6%1.8%
30 Day-8.4%-2.7%1.4%
90 Day-12.5%8.7%8.8%
1 Year-29.0%-29.0%9.4%6.7%22.7%20.1%
3 Year-72.9%-72.9%28.6%19.4%50.1%40.4%
5 Year-89.3%-89.3%24.6%11.8%72.9%53.9%

Price Volatility Vs. Market

How volatile is SCYNEXIS's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is SCYNEXIS undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SCYX ($0.98) is trading below our estimate of fair value ($27.26)

Significantly Below Fair Value: SCYX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SCYX is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: SCYX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SCYX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SCYX is overvalued based on its PB Ratio (9.2x) compared to the US Pharmaceuticals industry average (3.1x).


Next Steps

Future Growth

How is SCYNEXIS forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

45.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SCYX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SCYX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SCYX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SCYX's revenue (65.9% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: SCYX's revenue (65.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SCYX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has SCYNEXIS performed over the past 5 years?

-3.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SCYX is currently unprofitable.

Growing Profit Margin: SCYX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SCYX is unprofitable, and losses have increased over the past 5 years at a rate of -3.9% per year.

Accelerating Growth: Unable to compare SCYX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SCYX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.5%).


Return on Equity

High ROE: SCYX has a negative Return on Equity (-607.36%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is SCYNEXIS's financial position?


Financial Position Analysis

Short Term Liabilities: SCYX's short term assets ($29.0M) exceed its short term liabilities ($8.1M).

Long Term Liabilities: SCYX's short term assets ($29.0M) exceed its long term liabilities ($19.6M).


Debt to Equity History and Analysis

Debt Level: SCYX's debt to equity ratio (130.8%) is considered high.

Reducing Debt: Insufficient data to determine if SCYX's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: SCYX has a low level of unsold assets or inventory.

Debt Coverage by Assets: SCYX's debt is covered by short term assets (assets are 3.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SCYX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SCYX has less than a year of cash runway if free cash flow continues to reduce at historical rates of -18.4% each year


Next Steps

Dividend

What is SCYNEXIS's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.7%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate SCYX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SCYX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SCYX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SCYX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SCYX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Marco Taglietti (59yo)

4.8yrs

Tenure

US$1,114,895

Compensation

Dr. Marco Taglietti, M.D., has been the Chief Executive Officer of SCYNEXIS, Inc. since April 1, 2015 and has been President since September 24, 2015. Dr. Taglietti served as Senior Vice President, Head of ...


CEO Compensation Analysis

Compensation vs Market: Marco's total compensation ($USD1.11M) is above average for companies of similar size in the US market ($USD521.37K).

Compensation vs Earnings: Marco's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Marco Taglietti
CEO, President & Director4.8yrsUS$1.11m0.71% $679.8k
Eric Francois
Chief Financial Officer4.3yrsUS$664.70k0.028% $26.4k
David Angulo
Chief Medical Officer4.7yrsUS$768.61k0.13% $120.3k
Scott Sukenick
General Counsel & Corporate Secretary2.3yrsno data0.0030% $2.9k

4.5yrs

Average Tenure

49yo

Average Age

Experienced Management: SCYX's management team is considered experienced (4.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Marco Taglietti
CEO, President & Director4.8yrsUS$1.11m0.71% $679.8k
Armando Anido
Independent Director1.1yrsno datano data
David Hastings
Independent Director4.4yrsUS$72.75k0.033% $31.2k
Ann Hanham
Independent Director11.2yrsUS$72.75k0.0043% $4.1k
Guy MacDonald
Independent Chairman of the Board4.7yrsUS$81.83k0.041% $39.2k
Steven Gilman
Independent Director5yrsUS$69.00kno data
David Denning
Member of Scientific Advisory Board0yrsno datano data
Peter Pappas
Member of Scientific Advisory Board0yrsno datano data
Oliver Cornely
Member of Scientific Advisory Board0yrsno datano data
Barbara Alexander
Member of Scientific Advisory Board0yrsno datano data

4.8yrs

Average Tenure

60.5yo

Average Age

Experienced Board: SCYX's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SCYX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.1%.


Top Shareholders

Company Information

SCYNEXIS, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: SCYNEXIS, Inc.
  • Ticker: SCYX
  • Exchange: NasdaqGM
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$95.315m
  • Shares outstanding: 97.26m
  • Website: https://www.scynexis.com

Number of Employees


Location

  • SCYNEXIS, Inc.
  • 1 Evertrust Plaza
  • 13th Floor
  • Jersey City
  • New Jersey
  • 7302
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SCYXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMay 2014
135DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2014
0L49LSE (London Stock Exchange)YesCommon StockGBUSDMay 2014

Biography

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/16 01:52
End of Day Share Price2020/02/14 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.